(Q45877276)

English

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease

scientific article published on 5 May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Toya Ohashi

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Sayoko Iizuka

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Hiroyuki Ida

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Yoshikatsu Eto

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

publication date

5 May 2008

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

94

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

313-318

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.008

7 January 2021

Identifiers

10.1016/J.YMGME.2008.03.008

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/18456533

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45877276&oldid=2088274030"